07:35 AM EDT, 03/20/2026 (MT Newswires) -- Arch Biopartners ( ACHFF ) said Friday that St. Michael's Hospital (SMH) in Toronto, has begun patient dosing in Arch's Phase II trial evaluating LSALT peptide for the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI).

St. Michael's Hospital is the third Canadian site to recruit patients in the trial. At Royal Columbian Hospital in British Columbia, site start-up activities are ongoing ahead of starting patient recruitment.

Arch is also progressing feasibility and start-up discussions with additional cardiac surgery centres in Canada and the United States. Three prospective sites in the U.S. and one additional site in Ontario are currently under consideration, the company said.

The CS-AKI Phase II trial is an international study of LSALT peptide with a recruitment target of 240 patients. The primary objective of the trial is to evaluate the percentage of subjects with acute kidney injury (AKI) within seven days following on-pump (heart-lung machine) cardiac surgery. So far, no adverse events as related to LSALT peptide have been reported, a statement said.